Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

quote:

beeldscherm schreef op 30 oktober 2018 10:47:

56.350 euro voor onderzoek naar de ziekte van Pompe.

In het Erasmus MC (Rotterdam) is een nieuwe baanbrekende therapie in ontwikkeling, die als doel heeft het leven van kinderen met de ziekte van Pompe aanzienlijk te verbeteren. Metakids, een stichting die geld inzamelt voor onderzoek naar metabole ziekten, haalde hiervoor € 56.350 op tijdens hun jaarlijkse Lente Diner.

www.medicalfacts.nl/2018/03/13/56-350...

nu meen ik toch te weten dat Pharming in het verleden met het EMc Rotterdam samen werkten

quote:

BioTics schreef op 30 oktober 2018 10:43:

Hoe zit het met jouw huis?

waalwijk.nieuws.nl/nieuws/20161218/ro...

zo?

quote:

Techspec schreef op 30 oktober 2018 11:37:

nebula.wsimg.com/64ccab58fd60eb9444fa...

quote:

Jules B schreef op 30 oktober 2018 11:55:

[...]

Oud plaatje blijkt, het tweede blokje is namelijk terug in begin Phase III, danwel in geen enkele Phase want er is nog niets vernomen van aanlevering info aan de FDA.

quote:

Pharming is hot schreef op 30 oktober 2018 12:25:

First Berlin – Pharming Group NV Research Update (30/10/2018)
30 Oct 2018 By First Berlin Equity Research News
First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY rating and maintained his EUR 2.00 price target.

Abstract
Pharming's share price is down almost 40% on its highest closing prices this year of €1.57 reached on both 18 June and 30 January. In our view the reasons are three consecutive quarters (Q4/17-Q2/18) of flat sales of the recombinant human C1-inhibitor, Ruconest, the non-approval by the FDA of the product for prophylaxis in mid-September, and a general increase in risk aversion over the past few weeks. Last Thursday's news of a 30% sales jump in Q3/18 vs. Q2/18 has so far produced an 8.7% recovery in the stock price. We see more share price upside in coming quarters due to a) further growth in the number of hereditary angioedema (HAE) patients using Ruconest b) rich newsflow on the development of Ruconest in additional and underserved indications such as contrast-induced nephropathy, cardiac protection, pre-eclampsia, delayed graft function, and hemorrhagic shock. Each of these indications is potentially much more valuable than HAE. Investors should also note that competing C1-inhibitors are plasma-based. Plasma supplies are hardly sufficient to serve the HAE market, let alone the markets which Pharming is targeting with its more scalable recombinant product. c) leveraging of the recombinant platform to generate new drug candidates for diseases such as Pompe and Fabry d) generation of additional clinical data to secure approval for Ruconest in HAE prophylaxis. We maintain our Buy recommendation with a price target of €2.00.